Article

In the presentation, Dhawan will discuss Totus Medicines' proprietary drug discovery platform and first drug program, TOS-358, targeting the PI3Kα mutation, which impacts more than 500,000 people in the U.S. every year and drives a significant percentage of breast, colon, lung, bladder, stomach, and other cancers.